首页 > 最新文献

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie最新文献

英文 中文
Kefir peptides mitigate L-NAME-induced preeclampsia in rats through modulating hypertension and endothelial dysfunction. 开啡肽通过调节高血压和内皮功能障碍,减轻 L-NAME 引起的大鼠先兆子痫。
Pub Date : 2024-11-01 Epub Date: 2024-10-28 DOI: 10.1016/j.biopha.2024.117592
Yu-Hsuan Chen, Yo-Cheng Chang, Wan-Ju Wu, Min Chen, Chih-Ching Yen, Ying-Wei Lan, Hsu-Chen Cheng, Chuan-Mu Chen

Aim: Preeclampsia is a complex and serious pregnancy disorder that leads to maternal and neonatal mortality worldwide. Kefir peptides (KPs), derived from various prebiotic fermentations in whole milk by kefir grains, were investigated for their potential therapeutic effects. In this study, we used the L-NAME in drinking water to induce a preeclampsia-like condition in spontaneous hypertension stroke-prone (SHRSP) pregnant rats.

Main methods: The rats were assigned to five groups: the normal group (WKY rats), the untreated group (SHRSP rat control pregnant), the L-NAME/Mock group (SHRSP rats fed with L-NAME water), the L-NAME/KPs-LD group (SHRSP rats fed with L-NAME water and low-dose KPs diets), and the L-NAME/KPs-HD group (SHRSP rats fed with L-NAME water and high-dose KPs diets) for a 20-day experiment. Chorioallantois membrane (CAM) assay was applied for ex vivo angiogenesis study of KPs treatment.

Key findings: Data showed that rats in the L-NAME group developed severe hypertension, proteinuria, placental damage, and embryo resorption. Pre-administration of KPs significantly reduced hypertension, proteinuria, improved generalized endothelial dysfunction, and decreased levels of anti-HIF-1α, sFLT1, anti-TNF-α, and IL-6 in the placenta of SHRSP rats. In ex vivo CAM study, L-NAME administration in chicken embryos resulted in lower vessel density and hemorrhage; however, angiogenesis was observed after KPs-HD treatment.

Significance: The results indicate that kefir peptides improve renal lesions, prevent renal parenchyma damage, and balance endothelial and angiogenic dysfunction in both maternal and fetal sites in L-NAME-induced SHRSP pregnant rats.

目的:子痫前期是一种复杂而严重的妊娠疾病,在全球范围内导致产妇和新生儿死亡。克菲尔肽(KPs)由克菲尔谷物在全脂牛奶中进行各种益生菌发酵而得,其潜在的治疗效果受到了研究的关注。在本研究中,我们使用饮用水中的 L-NAME 诱导自发性高血压中风易感(SHRSP)妊娠大鼠出现类似先兆子痫的情况:将大鼠分为五组:正常组(WKY大鼠)、未处理组(SHRSP对照组妊娠大鼠)、L-NAME/Mock组(用L-NAME水喂养的SHRSP大鼠)、L-NAME/KPs-LD组(用L-NAME水和低剂量KPs膳食喂养的SHRSP大鼠)和L-NAME/KPs-HD组(用L-NAME水和高剂量KPs膳食喂养的SHRSP大鼠),进行为期20天的实验。主要研究结果:数据显示,L-NAME组大鼠出现了严重的高血压、蛋白尿、胎盘损伤和胚胎吸收。给药前服用 KPs 能显著降低 SHRSP 大鼠的高血压、蛋白尿,改善全身内皮功能障碍,降低胎盘中抗 HIF-1α、sFLT1、抗肿瘤坏死因子-α 和 IL-6 的水平。在体外 CAM 研究中,鸡胚胎服用 L-NAME 会导致血管密度降低和出血;但在 KPs-HD 处理后,观察到了血管生成:结果表明,在 L-NAME 诱导的 SHRSP 妊娠大鼠中,克菲尔肽可改善肾脏病变,防止肾实质损伤,平衡母体和胎儿部位的内皮和血管生成功能障碍。
{"title":"Kefir peptides mitigate L-NAME-induced preeclampsia in rats through modulating hypertension and endothelial dysfunction.","authors":"Yu-Hsuan Chen, Yo-Cheng Chang, Wan-Ju Wu, Min Chen, Chih-Ching Yen, Ying-Wei Lan, Hsu-Chen Cheng, Chuan-Mu Chen","doi":"10.1016/j.biopha.2024.117592","DOIUrl":"10.1016/j.biopha.2024.117592","url":null,"abstract":"<p><strong>Aim: </strong>Preeclampsia is a complex and serious pregnancy disorder that leads to maternal and neonatal mortality worldwide. Kefir peptides (KPs), derived from various prebiotic fermentations in whole milk by kefir grains, were investigated for their potential therapeutic effects. In this study, we used the L-NAME in drinking water to induce a preeclampsia-like condition in spontaneous hypertension stroke-prone (SHRSP) pregnant rats.</p><p><strong>Main methods: </strong>The rats were assigned to five groups: the normal group (WKY rats), the untreated group (SHRSP rat control pregnant), the L-NAME/Mock group (SHRSP rats fed with L-NAME water), the L-NAME/KPs-LD group (SHRSP rats fed with L-NAME water and low-dose KPs diets), and the L-NAME/KPs-HD group (SHRSP rats fed with L-NAME water and high-dose KPs diets) for a 20-day experiment. Chorioallantois membrane (CAM) assay was applied for ex vivo angiogenesis study of KPs treatment.</p><p><strong>Key findings: </strong>Data showed that rats in the L-NAME group developed severe hypertension, proteinuria, placental damage, and embryo resorption. Pre-administration of KPs significantly reduced hypertension, proteinuria, improved generalized endothelial dysfunction, and decreased levels of anti-HIF-1α, sFLT1, anti-TNF-α, and IL-6 in the placenta of SHRSP rats. In ex vivo CAM study, L-NAME administration in chicken embryos resulted in lower vessel density and hemorrhage; however, angiogenesis was observed after KPs-HD treatment.</p><p><strong>Significance: </strong>The results indicate that kefir peptides improve renal lesions, prevent renal parenchyma damage, and balance endothelial and angiogenic dysfunction in both maternal and fetal sites in L-NAME-induced SHRSP pregnant rats.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"180 ","pages":"117592"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "MicroRNA-30c functions as a tumor suppressor via targeting SNAI1 in esophageal squamous cell carcinoma" [Biomed. Pharmacother. 98 (2018) 680-686]. MicroRNA-30c 通过靶向食管鳞状细胞癌中的 SNAI1 发挥肿瘤抑制因子的功能》[Biomed. Pharmacother. 98 (2018) 680-686] 的更正。
Pub Date : 2024-10-01 Epub Date: 2024-09-02 DOI: 10.1016/j.biopha.2024.117376
Teng Ma, Ye Zhao, Qitong Lu, Yun Lu, Zhiyong Liu, Tao Xue, Yongfeng Shao
{"title":"Corrigendum to \"MicroRNA-30c functions as a tumor suppressor via targeting SNAI1 in esophageal squamous cell carcinoma\" [Biomed. Pharmacother. 98 (2018) 680-686].","authors":"Teng Ma, Ye Zhao, Qitong Lu, Yun Lu, Zhiyong Liu, Tao Xue, Yongfeng Shao","doi":"10.1016/j.biopha.2024.117376","DOIUrl":"10.1016/j.biopha.2024.117376","url":null,"abstract":"","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":" ","pages":"117376"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Studies on absorption mechanism and pharmacokinetic properties of albendazole-bile acid conjugate: In vivo and in vitro. 阿苯达唑-胆汁酸共轭物的吸收机制和药代动力学特性研究:体内和体外
Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI: 10.1016/j.biopha.2024.117400
Zhimei Guo, Shizhen Tang, Kaili Nie, Jingshuai Liu, Chunhui Hu

Purpose: To improve the oral bioavailability of albendazole (ABZ), a series of albendazole-bile acid conjugates (ABCs) were synthesized. ABC's transmembrane transport mechanism and in vivo pharmacokinetic properties were preliminarily studied.

Methods: The transmembrane transport mechanism of ABCs was studied using the Caco-2 monolayer cell model and intestinal perfusion model. The concentration of ABCs and ABZ were evaluated using High-Performance Liquid Chromatography (HPLC) and HPLC-Mass Spectrometry (HPLC-MS/MS).

Results: Compared to ABZ, better permeability was observed for different types and concentrations of ABCs using the Caco-2 monolayer cell model, with ABC-C8 showing the highest permeability. The transmembrane transport of ABCs was affected by ASBT inhibitors, indicating an ASBT-mediated active transport mechanism. Additionally, introducing cholic acid resulted in ABZ no longer being a substrate for P-gp, MRP2, and BCRP, effectively reversing ABZ efflux. In vivo unidirectional intestinal perfusion results in rats showed that ABCs altered the absorption site of ABZ from the jejunum to the ileum. The absorption efficiency of ABCs in each intestinal segment was higher than that of ABZ, and the transmembrane transport efficiency decreased with increasing concentrations of ASBT inhibitors. This further confirmed the presence of both passive diffusion and ASBT-mediated active transport mechanisms in the transport of ABCs. The solubility of ABCs in gastric juice and pharmacokinetics in rats showed that ABZ-C4 exhibited enhanced solubility. Moreover, ABCs significantly increased oral bioavailability compared to ABZ, with ABC-C4 showing an approximately 31-fold increase in bioavailability.

Conclusion: The transmembrane transport mechanism of ABCs involves a combination of ASBT-mediated active transport and passive diffusion. Moreover, the incorporation of BAs successfully reverses the efflux of ABZ by efflux proteins. Among the synthesized conjugates, ABC-C4 demonstrated superior dissolution behavior both in vitro and in vivo.

目的:为提高阿苯达唑(ABZ)的口服生物利用度,合成了一系列阿苯达唑-胆汁酸共轭物(ABCs)。初步研究了ABC的跨膜转运机制和体内药代动力学特性:方法:利用 Caco-2 单层细胞模型和肠道灌注模型研究了 ABCs 的跨膜转运机制。采用高效液相色谱法(HPLC)和HPLC-质谱法(HPLC-MS/MS)对ABCs和ABZ的浓度进行了评估:利用 Caco-2 单层细胞模型观察到,与 ABZ 相比,不同类型和浓度的 ABC 具有更好的渗透性,其中 ABC-C8 的渗透性最高。ABC的跨膜转运受到ASBT抑制剂的影响,这表明ASBT介导的主动转运机制。此外,引入胆酸会导致 ABZ 不再是 P-gp、MRP2 和 BCRP 的底物,从而有效逆转 ABZ 的外流。大鼠体内单向肠灌流结果显示,ABCs 改变了 ABZ 从空肠到回肠的吸收部位。ABCs在各肠段的吸收效率均高于ABZ,且跨膜转运效率随ASBT抑制剂浓度的增加而降低。这进一步证实了ABCs的转运同时存在被动扩散和ASBT介导的主动转运机制。ABCs 在胃液中的溶解度和在大鼠体内的药代动力学研究表明,ABZ-C4 的溶解度有所提高。此外,与 ABZ 相比,ABCs 能显著提高口服生物利用度,其中 ABC-C4 的生物利用度提高了约 31 倍:结论:ABCs 的跨膜转运机制涉及 ASBT 介导的主动转运和被动扩散的结合。此外,BA 的加入成功逆转了 ABZ 通过外排蛋白的外排。在合成的共轭物中,ABC-C4 在体外和体内均表现出优异的溶解性能。
{"title":"Studies on absorption mechanism and pharmacokinetic properties of albendazole-bile acid conjugate: In vivo and in vitro.","authors":"Zhimei Guo, Shizhen Tang, Kaili Nie, Jingshuai Liu, Chunhui Hu","doi":"10.1016/j.biopha.2024.117400","DOIUrl":"10.1016/j.biopha.2024.117400","url":null,"abstract":"<p><strong>Purpose: </strong>To improve the oral bioavailability of albendazole (ABZ), a series of albendazole-bile acid conjugates (ABCs) were synthesized. ABC's transmembrane transport mechanism and in vivo pharmacokinetic properties were preliminarily studied.</p><p><strong>Methods: </strong>The transmembrane transport mechanism of ABCs was studied using the Caco-2 monolayer cell model and intestinal perfusion model. The concentration of ABCs and ABZ were evaluated using High-Performance Liquid Chromatography (HPLC) and HPLC-Mass Spectrometry (HPLC-MS/MS).</p><p><strong>Results: </strong>Compared to ABZ, better permeability was observed for different types and concentrations of ABCs using the Caco-2 monolayer cell model, with ABC-C8 showing the highest permeability. The transmembrane transport of ABCs was affected by ASBT inhibitors, indicating an ASBT-mediated active transport mechanism. Additionally, introducing cholic acid resulted in ABZ no longer being a substrate for P-gp, MRP2, and BCRP, effectively reversing ABZ efflux. In vivo unidirectional intestinal perfusion results in rats showed that ABCs altered the absorption site of ABZ from the jejunum to the ileum. The absorption efficiency of ABCs in each intestinal segment was higher than that of ABZ, and the transmembrane transport efficiency decreased with increasing concentrations of ASBT inhibitors. This further confirmed the presence of both passive diffusion and ASBT-mediated active transport mechanisms in the transport of ABCs. The solubility of ABCs in gastric juice and pharmacokinetics in rats showed that ABZ-C4 exhibited enhanced solubility. Moreover, ABCs significantly increased oral bioavailability compared to ABZ, with ABC-C4 showing an approximately 31-fold increase in bioavailability.</p><p><strong>Conclusion: </strong>The transmembrane transport mechanism of ABCs involves a combination of ASBT-mediated active transport and passive diffusion. Moreover, the incorporation of BAs successfully reverses the efflux of ABZ by efflux proteins. Among the synthesized conjugates, ABC-C4 demonstrated superior dissolution behavior both in vitro and in vivo.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"179 ","pages":"117400"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "Monastrol suppresses invasion and metastasis in human colorectal cancer cells by targeting fascin independent of kinesin-Eg5 pathway" [Biomed. Pharmacother. 175 (2024) 116785]. 莫那甾醇通过靶向独立于驱动蛋白-Eg5 通路的 fascin 抑制人结直肠癌细胞的侵袭和转移》[Biomed. Pharmacother.
Pub Date : 2024-10-01 Epub Date: 2024-09-10 DOI: 10.1016/j.biopha.2024.117411
Begoña Alburquerque-González, Silvia Montoro-García, Ángel Bernabé-García, Manuel Bernabé-García, Priscila Campioni-Rodrigues, Alejandro Rodríguez-Martínez, Irene Luque, Tuula Salo, Alfonso Pérez-Garrido, Horacio Pérez-Sánchez, María Luisa Cayuela, Ginés Luengo-Gil, Enrico Luchinat, Fatima Postigo-Corrales, Tommaso Staderini, Francisco José Nicolás, Pablo Conesa-Zamora
{"title":"Corrigendum to \"Monastrol suppresses invasion and metastasis in human colorectal cancer cells by targeting fascin independent of kinesin-Eg5 pathway\" [Biomed. Pharmacother. 175 (2024) 116785].","authors":"Begoña Alburquerque-González, Silvia Montoro-García, Ángel Bernabé-García, Manuel Bernabé-García, Priscila Campioni-Rodrigues, Alejandro Rodríguez-Martínez, Irene Luque, Tuula Salo, Alfonso Pérez-Garrido, Horacio Pérez-Sánchez, María Luisa Cayuela, Ginés Luengo-Gil, Enrico Luchinat, Fatima Postigo-Corrales, Tommaso Staderini, Francisco José Nicolás, Pablo Conesa-Zamora","doi":"10.1016/j.biopha.2024.117411","DOIUrl":"10.1016/j.biopha.2024.117411","url":null,"abstract":"","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":" ","pages":"117411"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction notice to 'Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate' [Biomedicine & Pharmacotherapy, Volume 171 (2024) 116055]. 关于 "COVID-19第一波期间因同情使用羟氯喹而导致的死亡:估计 "的撤稿通知[《生物医学与药物治疗》,第171卷(2024年)116055]。
Pub Date : 2024-10-01 Epub Date: 2024-08-26 DOI: 10.1016/j.biopha.2024.117353
Alexiane Pradelle, Sabine Mainbourg, Steeve Provencher, Emmanuel Massy, Guillaume Grenet, Jean-Christophe Lega
{"title":"Retraction notice to 'Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate' [Biomedicine & Pharmacotherapy, Volume 171 (2024) 116055].","authors":"Alexiane Pradelle, Sabine Mainbourg, Steeve Provencher, Emmanuel Massy, Guillaume Grenet, Jean-Christophe Lega","doi":"10.1016/j.biopha.2024.117353","DOIUrl":"10.1016/j.biopha.2024.117353","url":null,"abstract":"","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":" ","pages":"117353"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "Exploring the molecular mechanisms of MSC-derived exosomes in Alzheimer's disease: Focus on autophagy, insulin and PI3K/Akt/mTOR signaling pathways" [Biomed. Pharmacother. 176 (2024) 116836]. 探索间充质干细胞衍生的外泌体在阿尔茨海默病中的分子机制:重点关注自噬、胰岛素和 PI3K/Akt/mTOR 信号通路" [Biomed. Pharmacother. 176 (2024) 116836]。
Pub Date : 2024-10-01 Epub Date: 2024-09-03 DOI: 10.1016/j.biopha.2024.117381
Faris Q B Alenzi
{"title":"Corrigendum to \"Exploring the molecular mechanisms of MSC-derived exosomes in Alzheimer's disease: Focus on autophagy, insulin and PI3K/Akt/mTOR signaling pathways\" [Biomed. Pharmacother. 176 (2024) 116836].","authors":"Faris Q B Alenzi","doi":"10.1016/j.biopha.2024.117381","DOIUrl":"10.1016/j.biopha.2024.117381","url":null,"abstract":"","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":" ","pages":"117381"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corilagin alleviates ferroptosis in diabetic retinopathy by activating the Nrf2 signaling pathway. 柯里拉京通过激活 Nrf2 信号通路缓解糖尿病视网膜病变中的铁蛋白沉着。
Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI: 10.1016/j.biopha.2024.117409
Wenxin Shi, Yuchen Dong, Shuyan Liu, Fengji Li, Chao Zhu

Background and purpose: Diabetic retinopathy (DR) is a prevalent complication of diabetes, with a rising global incidence, and can result in significant vision impairment and potential blindness in adults. Corilagin (COR) has been shown to regulate several pathological processes. However, the specific protective role and mechanism of action of COR in DR remain unknown.

Experimental approach: The protective effects and mechanisms of COR in DR were examined using the ARPE-19 cell line and C57BL/6 mice. Intraretinal tissue damage and molecular markers were evaluated to investigate the impact of COR on oxidative stress and cell death pathways.

Key results: In vitro, COR significantly reduced the cytotoxic effects of high glucose (HG) on ARPE-19 cells. Furthermore, COR also effectively decreased HG-induced lipid peroxidation, iron deposition, and ferroptosis and reduced damage to retinal tight junction proteins. Similarly, an in vivo study of streptozotocin (STZ)-induced DM mice showed that the daily gavage of COR for eight weeks notably alleviated DR. Mechanistically, COR activated the Nrf2 antioxidant signaling pathway both in vivo and in vitro, preventing HG-induced alterations in morphological and biochemical parameters. Notably, our study demonstrated that compared with controls, Nrf2 knockout mice and siNrf2-treated cells were more vulnerable to ferroptosis under HG conditions, and the protective effect of COR on DR was substantially diminished in these models.

Conclusion and implications: These data indicate that COR has a protective effect against HG-induced retinal injury via a mechanism associated with the Nrf2-dependent antioxidant pathway and ferroptosis regulation.

背景和目的:糖尿病视网膜病变(DR)是糖尿病的一种常见并发症,全球发病率不断上升,可导致成人视力严重受损并可能失明。研究表明,柯里拉京(COR)可调节多种病理过程。然而,COR 在糖尿病中的具体保护作用和作用机制仍然未知:实验方法:使用 ARPE-19 细胞系和 C57BL/6 小鼠研究了 COR 在 DR 中的保护作用和机制。实验方法:使用ARPE-19细胞系和C57BL/6小鼠研究了COR对DR的保护作用和机制,评估了视网膜内组织损伤和分子标记物,以研究COR对氧化应激和细胞死亡途径的影响:在体外,COR 能明显降低高糖(HG)对 ARPE-19 细胞的细胞毒性作用。此外,COR 还能有效降低 HG 诱导的脂质过氧化、铁沉积和铁变态反应,并减少视网膜紧密连接蛋白的损伤。同样,一项针对链脲佐菌素(STZ)诱导的DM小鼠的体内研究表明,连续八周每天灌胃COR可显著缓解DR。从机理上讲,COR在体内和体外都激活了Nrf2抗氧化信号通路,防止了HG诱导的形态学和生化参数的改变。值得注意的是,我们的研究表明,与对照组相比,Nrf2基因敲除小鼠和siNrf2处理的细胞在HG条件下更容易发生铁变态反应,在这些模型中,COR对DR的保护作用大大减弱:这些数据表明,COR对HG诱导的视网膜损伤具有保护作用,其机制与依赖于Nrf2的抗氧化途径和铁突变调节有关。
{"title":"Corilagin alleviates ferroptosis in diabetic retinopathy by activating the Nrf2 signaling pathway.","authors":"Wenxin Shi, Yuchen Dong, Shuyan Liu, Fengji Li, Chao Zhu","doi":"10.1016/j.biopha.2024.117409","DOIUrl":"10.1016/j.biopha.2024.117409","url":null,"abstract":"<p><strong>Background and purpose: </strong>Diabetic retinopathy (DR) is a prevalent complication of diabetes, with a rising global incidence, and can result in significant vision impairment and potential blindness in adults. Corilagin (COR) has been shown to regulate several pathological processes. However, the specific protective role and mechanism of action of COR in DR remain unknown.</p><p><strong>Experimental approach: </strong>The protective effects and mechanisms of COR in DR were examined using the ARPE-19 cell line and C57BL/6 mice. Intraretinal tissue damage and molecular markers were evaluated to investigate the impact of COR on oxidative stress and cell death pathways.</p><p><strong>Key results: </strong>In vitro, COR significantly reduced the cytotoxic effects of high glucose (HG) on ARPE-19 cells. Furthermore, COR also effectively decreased HG-induced lipid peroxidation, iron deposition, and ferroptosis and reduced damage to retinal tight junction proteins. Similarly, an in vivo study of streptozotocin (STZ)-induced DM mice showed that the daily gavage of COR for eight weeks notably alleviated DR. Mechanistically, COR activated the Nrf2 antioxidant signaling pathway both in vivo and in vitro, preventing HG-induced alterations in morphological and biochemical parameters. Notably, our study demonstrated that compared with controls, Nrf2 knockout mice and siNrf2-treated cells were more vulnerable to ferroptosis under HG conditions, and the protective effect of COR on DR was substantially diminished in these models.</p><p><strong>Conclusion and implications: </strong>These data indicate that COR has a protective effect against HG-induced retinal injury via a mechanism associated with the Nrf2-dependent antioxidant pathway and ferroptosis regulation.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"179 ","pages":"117409"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sulforaphane improves post-resuscitation myocardial dysfunction by inhibiting cardiomyocytes ferroptosis via the Nrf2/IRF1/GPX4 pathway. 红景天通过Nrf2/IRF1/GPX4途径抑制心肌细胞铁突变,从而改善复苏后心肌功能障碍。
Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI: 10.1016/j.biopha.2024.117408
Zhongjun Zheng, Jiefeng Xu, Yi Mao, Zhihan Mei, Jinjiang Zhu, Pin Lan, Xianlong Wu, Shanxiang Xu, Mao Zhang

Background: Ferroptosis is an important type of cell death contributing to myocardial dysfunction induced by whole body ischemia reperfusion following cardiac arrest (CA) and resuscitation. Sulforaphane (SFN), known as the activator of the nuclear factor E2-related factor 2 (Nrf2), has been proven to effectively alleviate regional myocardial ischemia reperfusion injury. The present study was designed to investigate whether SFN could improve post-resuscitation myocardial dysfunction by inhibiting cardiomyocytes ferroptosis and its potential regulatory mechanism.

Methods and results: An in vivo pig model of CA and resuscitation was established. Hypoxia/reoxygenation (H/R)-stimulated AC16 cardiomyocytes was constructed as an in vitro model to simulate the process of CA and resuscitation. In vitro experiment, SFN reduced ferroptosis-related ferrous iron, lipid reactive oxygen species, and malondialdehyde, increased glutathione, and further promoted cell survival after H/R stimulation in AC16 cardiomyocytes. Mechanistically, the activation of Nrf2 with the SFN decreased interferon regulatory factor 1 (IRF1) expression, then reduced its binding to the promoter of glutathione peroxidase 4 (GPX4), and finally recovered the latter's transcription after H/R stimulation in AC16 cardiomyocytes. In vivo experiment, SFN reversed abnormal expression of IRF1 and GPX4, inhibited cardiac ferroptosis, and improved myocardial dysfunction after CA and resuscitation in pigs.

Conclusions: SFN could effectively improve myocardial dysfunction after CA and resuscitation, in which the mechanism was potentially related to the inhibition of cardiomyocytes ferroptosis through the regulation of Nrf2/IRF1/GPX4 pathway.

背景:心脏骤停(CA)和复苏后全身缺血再灌注导致心肌功能障碍,而铁蛋白沉积是导致心肌功能障碍的一种重要细胞死亡类型。被称为核因子 E2 相关因子 2(Nrf2)激活剂的茜草素(SFN)已被证实能有效缓解区域性心肌缺血再灌注损伤。本研究旨在探讨 SFN 是否能通过抑制心肌细胞铁突变及其潜在调控机制来改善复苏后心肌功能障碍:方法和结果:建立了CA和复苏猪体内模型。低氧/复氧(H/R)刺激的 AC16 心肌细胞作为体外模型模拟 CA 和复苏过程。在体外实验中,SFN降低了AC16心肌细胞H/R刺激后与铁变态反应相关的亚铁、脂质活性氧和丙二醛,增加了谷胱甘肽,进一步促进了细胞存活。从机理上讲,SFN激活Nrf2可降低干扰素调节因子1(IRF1)的表达,进而减少其与谷胱甘肽过氧化物酶4(GPX4)启动子的结合,最终恢复后者在AC16心肌细胞受到H/R刺激后的转录。在体内实验中,SFN逆转了IRF1和GPX4的异常表达,抑制了心脏铁变态反应,改善了猪CA和复苏后的心肌功能障碍:结论:SFN能有效改善CA和复苏后的心肌功能障碍,其机制可能与通过调节Nrf2/IRF1/GPX4通路抑制心肌细胞嗜铁有关。
{"title":"Sulforaphane improves post-resuscitation myocardial dysfunction by inhibiting cardiomyocytes ferroptosis via the Nrf2/IRF1/GPX4 pathway.","authors":"Zhongjun Zheng, Jiefeng Xu, Yi Mao, Zhihan Mei, Jinjiang Zhu, Pin Lan, Xianlong Wu, Shanxiang Xu, Mao Zhang","doi":"10.1016/j.biopha.2024.117408","DOIUrl":"10.1016/j.biopha.2024.117408","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis is an important type of cell death contributing to myocardial dysfunction induced by whole body ischemia reperfusion following cardiac arrest (CA) and resuscitation. Sulforaphane (SFN), known as the activator of the nuclear factor E2-related factor 2 (Nrf2), has been proven to effectively alleviate regional myocardial ischemia reperfusion injury. The present study was designed to investigate whether SFN could improve post-resuscitation myocardial dysfunction by inhibiting cardiomyocytes ferroptosis and its potential regulatory mechanism.</p><p><strong>Methods and results: </strong>An in vivo pig model of CA and resuscitation was established. Hypoxia/reoxygenation (H/R)-stimulated AC16 cardiomyocytes was constructed as an in vitro model to simulate the process of CA and resuscitation. In vitro experiment, SFN reduced ferroptosis-related ferrous iron, lipid reactive oxygen species, and malondialdehyde, increased glutathione, and further promoted cell survival after H/R stimulation in AC16 cardiomyocytes. Mechanistically, the activation of Nrf2 with the SFN decreased interferon regulatory factor 1 (IRF1) expression, then reduced its binding to the promoter of glutathione peroxidase 4 (GPX4), and finally recovered the latter's transcription after H/R stimulation in AC16 cardiomyocytes. In vivo experiment, SFN reversed abnormal expression of IRF1 and GPX4, inhibited cardiac ferroptosis, and improved myocardial dysfunction after CA and resuscitation in pigs.</p><p><strong>Conclusions: </strong>SFN could effectively improve myocardial dysfunction after CA and resuscitation, in which the mechanism was potentially related to the inhibition of cardiomyocytes ferroptosis through the regulation of Nrf2/IRF1/GPX4 pathway.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"179 ","pages":"117408"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "GPR41 and GPR43: From development to metabolic regulation" [Biomed. Pharmacother. 175 (2024) 116735]. 更正 "GPR41 和 GPR43:从发育到代谢调节"[Biomed. Pharmacother. 175 (2024) 116735]。
Pub Date : 2024-10-01 Epub Date: 2024-08-31 DOI: 10.1016/j.biopha.2024.117380
Do-Hyung Lee, Min-Tae Kim, Joo-Hui Han
{"title":"Corrigendum to \"GPR41 and GPR43: From development to metabolic regulation\" [Biomed. Pharmacother. 175 (2024) 116735].","authors":"Do-Hyung Lee, Min-Tae Kim, Joo-Hui Han","doi":"10.1016/j.biopha.2024.117380","DOIUrl":"10.1016/j.biopha.2024.117380","url":null,"abstract":"","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":" ","pages":"117380"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Facile engineered macrophages-derived exosomes-functionalized PLGA nanocarrier for targeted delivery of dual drug formulation against neuroinflammation by modulation of microglial polarization in a post-stroke depression rat model. 在中风后抑郁大鼠模型中通过调节小胶质细胞极化靶向递送抗神经炎症的双重药物配方
Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI: 10.1016/j.biopha.2024.117263
Zhongyue Lv, Cui Zhao, Xiping Wu, Yinqi Chen, Cheng Zheng, Xiaoling Zhang, Yifei Xu, Lujia Zhu, Haifeng Wang, Guomin Xie, Wu Zheng

Post-stroke depression (POSD) is a common difficulty and most predominant emotional syndrome after stroke often consequences in poor outcomes. In the present investigation, we have designed and studied the neurologically active celastrol/minocycline encapsulated with macrophages-derived exosomes functionalized PLGA nanoformulations (CMC-EXPL) to achieve enhanced anti-inflammatory behaviour and anti-depressant like activity in a Rat model of POSD. The animal model of POSD was established through stimulating process with chronic unpredictable mild stress (CUM) stimulations after procedure of middle cerebral artery occlusion (MCAO). Neuronal functions and Anti-inflammation behaviours were observed by histopathological (H&E) examination and Elisa analyses, respectively. The anti-depressive activity of the nanoformulations treated Rat models were evaluated by open-field and sucrose preference test methods. Microglial polarization was evaluated via flow-cytometry and qRT-PCR observations. The observed results exhibited that prepared nanoformulations reduced the POSD-stimulated depressive-like activities in rat models as well alleviated the neuronal damages and inflammatory responses in the cerebral hippocampus. Importantly, prepared CMC-EXPL nanoformulation effectively prevented the M1 pro-inflammatory polarization and indorsed M2 anti-inflammatory polarization, which indicates iNOS and CD86 levels significantly decreased and upsurged Arg-1 and CD206 levels. CMC-EXPL nanoformulation suggestively augmented anti-depressive activities and functional capability and also alleviated brain inflammation in POSD rats, demonstrating its therapeutic potential for POSD therapy.

脑卒中后抑郁(POSD)是脑卒中后常见的一种困难和最主要的情绪综合征,往往会导致不良后果。在本研究中,我们设计并研究了具有神经活性的塞拉司琼/三环素与巨噬细胞衍生的外泌体功能化聚乳酸(PLGA)纳米制剂(CMC-EXPL),以在大鼠 POSD 模型中实现增强的抗炎行为和类似抗抑郁剂的活性。POSD动物模型是在大脑中动脉闭塞(MCAO)术后通过慢性不可预知轻度应激(CUM)刺激过程建立的。通过组织病理学(H&E)检查和 Elisa 分析分别观察了神经元功能和抗炎行为。纳米制剂处理大鼠模型的抗抑郁活性通过开场和蔗糖偏好试验方法进行评估。通过流式细胞仪和 qRT-PCR 观察评估了微神经胶质细胞的极化。观察结果表明,制备的纳米制剂降低了 POSD 刺激大鼠模型的抑郁样活动,并减轻了大脑海马的神经元损伤和炎症反应。重要的是,制备的CMC-EXPL纳米制剂能有效阻止M1促炎极化,支持M2抗炎极化,这表明iNOS和CD86水平显著下降,Arg-1和CD206水平上升。CMC-EXPL纳米制剂可增强POSD大鼠的抗抑郁活性和功能能力,缓解脑部炎症,显示了其治疗POSD的潜力。
{"title":"Facile engineered macrophages-derived exosomes-functionalized PLGA nanocarrier for targeted delivery of dual drug formulation against neuroinflammation by modulation of microglial polarization in a post-stroke depression rat model.","authors":"Zhongyue Lv, Cui Zhao, Xiping Wu, Yinqi Chen, Cheng Zheng, Xiaoling Zhang, Yifei Xu, Lujia Zhu, Haifeng Wang, Guomin Xie, Wu Zheng","doi":"10.1016/j.biopha.2024.117263","DOIUrl":"10.1016/j.biopha.2024.117263","url":null,"abstract":"<p><p>Post-stroke depression (POSD) is a common difficulty and most predominant emotional syndrome after stroke often consequences in poor outcomes. In the present investigation, we have designed and studied the neurologically active celastrol/minocycline encapsulated with macrophages-derived exosomes functionalized PLGA nanoformulations (CMC-EXPL) to achieve enhanced anti-inflammatory behaviour and anti-depressant like activity in a Rat model of POSD. The animal model of POSD was established through stimulating process with chronic unpredictable mild stress (CUM) stimulations after procedure of middle cerebral artery occlusion (MCAO). Neuronal functions and Anti-inflammation behaviours were observed by histopathological (H&E) examination and Elisa analyses, respectively. The anti-depressive activity of the nanoformulations treated Rat models were evaluated by open-field and sucrose preference test methods. Microglial polarization was evaluated via flow-cytometry and qRT-PCR observations. The observed results exhibited that prepared nanoformulations reduced the POSD-stimulated depressive-like activities in rat models as well alleviated the neuronal damages and inflammatory responses in the cerebral hippocampus. Importantly, prepared CMC-EXPL nanoformulation effectively prevented the M1 pro-inflammatory polarization and indorsed M2 anti-inflammatory polarization, which indicates iNOS and CD86 levels significantly decreased and upsurged Arg-1 and CD206 levels. CMC-EXPL nanoformulation suggestively augmented anti-depressive activities and functional capability and also alleviated brain inflammation in POSD rats, demonstrating its therapeutic potential for POSD therapy.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"179 ","pages":"117263"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1